Worth Venture Partners, LLC Paratek Pharmaceuticals, Inc. Transaction History

Worth Venture Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.37 - $2.54 $499,488 - $926,058	-364,590 Reduced 35.66%	657,885 $1.67 Million
Q4 2022 Feb 14, 2023	BUY	$1.67 - $2.51 $88,137 - $132,470	52,777 Added 5.44%	1,022,475 $1.91 Million
Q2 2022 Aug 15, 2022	BUY	$1.73 - $3.09 $321,722 - $574,638	185,967 Added 23.73%	969,698 $2.37 Million
Q1 2022 May 16, 2022	BUY	$2.94 - $4.77 $667,083 - $1.08 Million	226,899 Added 40.75%	783,731 $2.33 Million
Q4 2021 Feb 14, 2022	BUY	$4.07 - $5.3 $681,285 - $887,177	167,392 Added 42.98%	556,832 $2.5 Million
Q3 2021 Nov 15, 2021	BUY	$4.7 - $7.24 $742,919 - $1.14 Million	158,068 Added 68.32%	389,440 $1.89 Million
Q2 2021 Aug 16, 2021	BUY	$6.81 - $10.93 $274,299 - $440,249	40,279 Added 21.08%	231,372 $1.58 Million
Q4 2020 Feb 17, 2021	BUY	$4.58 - $7.14 $84,986 - $132,489	18,556 Added 10.75%	191,093 $1.2 Million
Q3 2020 Nov 16, 2020	BUY	$4.19 - $6.69 $722,930 - $1.15 Million	172,537 New	172,537 $933,000

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Worth Venture Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Worth Venture Partners, LLC with notifications on news.